Mash-Hud is a qualified patent attorney who is experienced in drafting and prosecution work in semiconductor technologies, opto-electronics, mobile telecommunications, software, medical devices and oil well technology. He also has experience at opposition proceedings before the EPO.

After completing a BSc degree with first class honours in Electronics and Computing, Mash-Hud moved to the University of Cambridge where he gained an MPhil and PhD in Solid State Engineering. Mash-Hud's MPhil research was directed to modelling novel power devices for emerging technologies. He then carried out further research for his PhD on silicon-on-insulator (SOI) based high voltage devices for power ICs and nanoscale transistors using silicon nanowires.

Mash-Hud joined Marks & Clerk in 2008 and qualified as a European Patent Attorney and UK Chartered Patent Attorney in 2013. Mash-Hud has been recognised as a rising star by Managing Intellectual Property, IP Stars, 2017 and 2018.

Doctor in Behavioral Sciences, coach-trainer and professional musician.

Eija is currently the CEO and co-founder of an awarded applied games start up called Altogame. Altogame is a game-changing virtual multiplayer environment for innovation, collaboration and training simulations.

Prior to founding Altogame, Eija developed an internationally unique face-to-face coaching method integrating musicians ́ professional top performance and well-being. She wrote the first Finnish coaching related doctoral thesis on the subject, and the first white paper on how to transform organizations by using arts-derived interventions. Eija has created and run programs on how to integrate agility, innovation and top performance in numerous organizations including Nokia, Kone, UCL, Aalto University, and Anglia-Ruskin University. She is very experienced as public speaker, coach and trainer. The first part of her professional career Eija was an internationally performing musician.

In regard to start-up scenes and communities, Eija has been a start-up member of numerous accelerators/hubs and participated various programs. She has herself acted as a mentor and delivered training to start-ups e.g. in Aalto University and University of the Arts Helsinki (Finland). In addition to the business subjects, her training has included also Human Factor themes such as working with customers (e.g. to understand the real problem), pitching to different audiences (e.g. from academic to corporate, customer or investor viewpoint and language), top performing (multi-cultural, cross-disciplinary etc.) teams, creativity at work, self-leadership, persuasion skills and performing under pressure.

Currently Eija is based in Cambridge, UK.

Bioinformatics scientist specialised in genome analysis with 15 years of experience in software development and project management. Fiona left her job at Illumina Cambridge in 2013 to pursue her vision of enabling efficient genomic data sharing and founded the charity DNAdigest. In August 2014 she founded Repositive as a spin out of DNADigest.

Keywords:
- social enterprise and social impact
- business model development
- software products
- selling to biopharma and CROs
- raising funding
- strategic partnerships

Matthew specialises in the fields of electronics, mobile telecommunications, software and mechanical devices. He has experience in the drafting, filing and prosecution of patent applications in the UK, Europe, USA, Asia, and other jurisdictions across the world.

Having been awarded the prize of Young Electronic Designer of the Year Award in 2002, Matthew then went on to graduate from Leeds University with a first class Master’s Degree in Electronic Engineering. Matthew joined the patent profession in 2008 working for a London based firm of patent & trademark attorneys. Matthew qualified as a European Patent Attorney in 2012 and a UK Chartered Patent Attorney in 2013. He joined Marks & Clerk in 2015.

Katarzyna joined the IMED Oncology team at AstraZeneca as a Drug project Information Manager, taking responsibility for scientific information management governance. In this role Katarzyna oversees and aligns scientific communication strategies with the oncology business acumen.
Prior to this role, she worked for an emerging Clinical Research Organisation in Cambridgeshire, being accountable for clinical project management and cultivating relationships with key business partners. At Amgen, she conducted a business insight project to evaluate market share.

Katarzyna is passionate about oncology and neuroscience R&D, though encouraging open innovation knowledge transfer, scientific communications. Her area of interest lies in the new applications of AI technologies in Healthcare. For the past few years, she has enjoyed gaining experience working both with small businesses and start-ups in the UK, and also global organisations (the Alzheimer’s Society, WHO, and the United Nations internationally.

Katarzyna completed her MSc in Clinical Drug Development and Management at the Queen Mary University/UCL, focused on clinical research recruitment strategies. She holds a BSc degree in Biomedicine and an Eng. degree in Pharmaceutical Technology. As a part of the Erasmus exchange programme she collaborated with the Max Planck Institute for Innovation and Competition in Munich, and the Uppsala University where she focused on pharmaceutical IP innovation.

Dr Karolina Zapadka is a co-founder and Managing Director at ZapaBio Ltd, a global consulting company which aims to support Bioscience Innovation. Her interests lie in the life sciences and healthcare industry and the interface between business and science, entrepreneurship and technology transfer.

Karolina has a strong interest in knowledge exchange and in facilitating collaborations between Academia, Industry and Government. As such she joined the Oxbridge Biotech Roundtable (OBR) in 2013 as President of Cambridge Chapter, where she was highly involved in organising workshops and seminars, as well as setting up and marketing of the OneStart competition. For the past almost eight years she has been actively involved in Cambridge ecosystem, first working in an emerging biotech company (Arecor Ltd.), later during her PhD and postdoc in non-profit organisations. She is a founding member and a former Executive Team Member of Global Innovation Forum Ltd (IF), a global, interdisciplinary network of young researchers, industry
professionals and policy makers. Moreover, she participated in many entrepreneurship courses run by Cambridge Judge Business School including: BioInno Entrepreneurship Course in 2014, a Life Sciences Start-up Weekend with AstraZeneca in 2015, Accelerator Programme, Ignite 2016 & 2017.

She has over nine years of professional experience in research work in both academia and the industry. Her academic work includes a double research Master diploma from Jagiellonian (Poland) and Lund (Sweden) University, PhD from Cambridge (UK) and Postdoctoral work between University of Cambridge and MedImmune. Her research interests are focused on diabetes, drug discovery, stability and formulations of peptide pharmaceuticals.

Dr John Carrigan has a strange job of Chief scientist and innovation (investment opportunity) seeker for SOSV (Sean O Sullivan Ventures), one of the worlds most active early stage investors. His principal interests within the firm are bioscience investments which are developed in RebelBio, a dedicated investment program recently established by Dr Carrigan and his team at Imperial College White City. Dr Carrigan began his career as an academic biochemist where he published papers concerning protein chemistry and metabolomics. Subsequently he into the world of start ups with Dublin based AERBIO, which was acquired by green biochemical company Cellulac ltd in 2013. Away from his work with SOSV, he acts as an expert advisor for the European Innovation Council's SME (Small Medium Enterprise) instrument. An initiative to fund the most promising start up bioscience companies across Europe.

Philippa is a Licensing and Ventures Manager at Oxford University Innovation (OUI) in the Digital Health and Medical Devices team. She has worked for the past three years with researchers across the University of Oxford to help them create impact with their ideas. Philippa has expertise in developing early stage ideas into business propositions, which includes IP landscape analysis, market analysis, building business plans, CE marking and regulatory issues, advice on app development, and licence negotiations. Whilst a large number of her projects are in the digital health space, Philippa has facilitated spinout companies from the Humanities and Social Sciences Divisions. She is delighted to be increasingly working with projects focused on mental health issues.

Philippa also has a passion for social enterprises, companies that put purpose before profit, and is part of the team offering a support to create these entities from the University. Philippa was part of the team that set up OxReach, the crowdfunding platform for social good projects from the University of Oxford. She has supported four successful campaigns which have all benefited substantially from the public support that they received and are now creating local and international impact

David is a social entrepreneur and experienced technologist with a passion for innovation in healthcare and specifically paediatrics. He has had a career with IBM spanning nearly 20 years and has spent the last three years working within IBM’s artificial intelligence arm, Watson. David began the role of Innovation and AI Lead at the beginning of 2018 with the remit of exploring new ways for healthcare organisations to embrace IBM’s healthcare and Cognitive technologies.

Outside of IBM, David runs a UK based children’s charity, Thinking of Oscar, which supports children and their families whilst in hospital care, funding innovation and technology over and above that provided by the UK health services. Thinking of Oscar was set up following the sudden death of his son Oscar in 2014 and has raised over £200,000. David and his wife Hannah work closely with UK Children’s hospitals to identify projects where they can make a difference. David is a member of The International Society for Paediatric Innovation (iSPI) which has been formed to address the unmet needs of an open global network, enabling unique opportunities for paediatric leaders to be at the cutting edge of technological innovations. His ultimate goal is to see artificial intelligence technologies, such as Watson, pervasively used in paediatric healthcare to assist with knowledge share, decision making and ultimately save lives.

David is a ‘Digital Health Expert in Residence’ at the University of Oxford supporting it’s healthcare start-up incubator, The Hill. David is also an advisor to a number of boards and faculties looking at health technology, child health and the future of medicine. David lives in rural Oxfordshire in the UK, with his wife and 3 young children. David is a keen triathlete, cricketer and wine enthusiast, holding an Advanced Level 3 qualification from the Wine and Spirit Education Trust. He is building up to compete in his first full Ironman in July 2019.

Nick is an NHD Trust Digital Innovation & Population Health Lead, a startup entrepreneur and co-founder of health innovation lab. He has a background as a neurosurgeon with over 15 years of front line clinical experience in the NHS.